(Q46950109)

26 December 2017

title

Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel) (English)

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04693.X

2 December 2024

1 reference

M. S. Khan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21585408

2 December 2024

F. El-Khouly

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21585408

2 December 2024

P. Davies

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21585408

2 December 2024

C. Toumpanakis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21585408

2 December 2024

M. E. Caplin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21585408

2 December 2024

language of work or name

English

0 references

publication date

17 May 2011

1 reference

26 December 2017

full work available at URL

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2036.2011.04693.x

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21585408

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2036.2011.04693.x

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04693.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2011.04693.x/fullpdf

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04693.X

Alimentary Pharmacology & Therapeutics

2 December 2024

published in

1 reference

26 December 2017

volume

1 reference

26 December 2017

issue

1 reference

26 December 2017

page(s)

235-242

1 reference

26 December 2017

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Distribution of somatostatin receptors in normal and tumor tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Expression of somatostatin and dopamine 2 receptors in neuroendocrine tumours and the potential role for new biotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Somatostatin inhibits diarrhea in the carcinoid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Somatostatin, gastrointestinal peptides, and the carcinoid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

A 5-decade analysis of 13,715 carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04693.X

The history of somatostatin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04693.X

Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04693.X

Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04693.X

Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04693.X

Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04693.X

Neuroendocrine tumors. Biotherapy

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04693.X

Long-Term Management of the Carcinoid Syndrome Treatment with octreotide alone and in combination with alpha-interferon

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04693.X

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group

2 December 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.2011.04693.X

2 December 2024

Identifiers

1 reference

26 December 2017

1 reference

26 December 2017